Status:
COMPLETED
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
Lead Sponsor:
Omeros Corporation
Conditions:
Cataract
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintai...
Eligibility Criteria
Inclusion
- Competent and willing to voluntarily provide informed consent
- 18 years of age or older
- In good general health needing to undergo cataract extraction with lens replacement surgery in one eye, under topical anesthesia
- Other inclusion criteria to be evaluated by the investigator
Exclusion
- No allergies to the medications and/or the active ingredients of any of the study medications
- No medications with the same activities as the of the active ingredients in OMS302 for defined time intervals prior to and after surgery
- No other significant eye injuries, eye conditions or general medical conditions likely to interfere with the evaluation of the study medication
- Other exclusion criteria to be evaluated by the investigator
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT01193127
Start Date
July 1 2010
End Date
February 1 2011
Last Update
August 28 2014
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Chandler, Arizona, United States, 85224
2
Glendale, Arizona, United States, 85308
3
Little Rock, Arkansas, United States, 72205
4
Los Angeles, California, United States, 90013